CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.
March 15th 2024
Breyanzi has been approved by the FDA for some previously treated patients with CLL or SLL — marking the first CAR-T cell therapy approved for this patient population.
Crossover Study Offers Additional Line of Therapy for Patients with Relapsed CLL/SLL
December 18th 2018Single agent Copiktra (duvelisib) induced robust, durable responses in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who experienced disease progression after treatment with Arzerra (ofatumumab).
Frontline BTK Inhibitor Regimen Improves Outcomes in CLL/SLL
December 14th 2018Frontline use of Imbruvica (ibrutinib) in combination with Gazyva (obinutuzumab) significantly reduced the risk for disease progression or death among patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), especially in those with high-risk disease.
Curcumin and Vitamin D Treatment May Stabilize Disease in Patients with CLL and SLL
December 7th 2018In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), high doses of curcumin and vitamin D could help stabilize the disease, according to new research presented at the American Society of Hematology’s (ASH) Annual Meeting in San Diego.